BullFrog AI Holdings, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $1.6 million, a decrease from a net loss of $2.0 million in the same period of 2025. The company did not generate any revenue during the quarter, consistent with the previous year. Operating expenses totaled $1.6 million, down from $2.1 million year-over-year, primarily due to reduced research and development costs and lower general and administrative expenses. The company’s cash and cash equivalents increased significantly to approximately $5.1 million as of March 31, 2026, compared to $2.2 million at the end of 2025.
In terms of operational developments, BullFrog AI has made strides in its strategic partnerships and product offerings. The company entered into a feasibility agreement with a global pharmaceutical company in March 2026, which aims to leverage its proprietary bfLEAP™ platform for drug target discovery. This agreement is expected to yield milestone payments upon the delivery of specific deliverables. Additionally, the company has continued to expand its collaborations, including a strategic partnership with Sygnature Discovery to introduce its AI-driven data insights platform to a broader biopharma client base.
The company’s stockholder equity rose to $4.9 million as of March 31, 2026, up from $2.1 million at the end of 2025, largely due to successful capital raises through its At-The-Market Sales Agreement and an equity line of credit. During the first quarter, BullFrog AI raised approximately $4.6 million from the sale of common stock, which contributed to its improved liquidity position. The total number of shares outstanding increased to 18,447,105, reflecting the company's ongoing efforts to secure funding for its operations and growth initiatives.
Looking ahead, BullFrog AI's management has expressed cautious optimism regarding its financial outlook, emphasizing the need for additional capital to support its strategic objectives. The company plans to continue pursuing partnerships and collaborations to enhance its product offerings and expand its market presence. However, management has also acknowledged the inherent risks associated with its business model, including the potential need for further capital raises and the challenges of maintaining compliance with Nasdaq listing requirements. The company is currently under a mandatory panel monitor for compliance with stockholder equity rules, following a recent determination by Nasdaq that it had regained compliance.
Overall, BullFrog AI Holdings, Inc. is navigating a challenging financial landscape while actively pursuing strategic partnerships and product development initiatives aimed at leveraging its AI-driven platform for advancements in drug development. The company remains focused on enhancing its operational capabilities and securing the necessary funding to sustain its growth trajectory.
About BullFrog AI Holdings, Inc.
Bullfrog AI Holdings, Inc. develops and applies proprietary artificial intelligence and machine learning technology, bfLEAP™, to enhance drug development by analyzing complex preclinical and clinical data. The company focuses on rescuing and advancing therapeutics, particularly in oncology and rare diseases, through data-driven patient stratification and trial optimization. Its business model includes licensing drug rights, collaborative partnerships, and fee-for-service analytics targeting biopharmaceutical companies and research institutions.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.